Abstract 1724
Background
In 2018 the role of clinical nurse specialist (CNS) was implemented in an ambulatory setting at our cancer research center in Italy. CNSs received specific training before taking on their new role. Although measuring the impact of CNSs is vital to support decision-making on the development and implementation of advanced nursing roles, the identification of indicators reflecting their impact on clinical practice remains one of the most challenging nursing research issues, mainly because of the complexity of the contributors who determine patient and organizational outcomes.
Methods
The study evaluated indicators measuring the implementation process and the impact of the CNS role one year after its introduction. Indicators for the former were: CNS interface mapping in disease pathways, participation rate of CNS in multidisciplinary team (MDT) meetings, and number of training hours/CNS on specific cancers. Indicators for the latter were: patient satisfaction with CNS (survey), compliance with priority criteria for waiting times for the first visit, total number of documented CNS-patient communications (i.e. first nursing interviews with new patients, phone interviews); and number of improvement projects to which CNSs contributed.
Results
One year after CNS introduction, pathway mapping was 100%; MDT meeting participation 95%; training hours 40.5/CNS vs. defined standard of 30 hours. 83.2% of interviewed patients were very satisfied with CNSs. An average of 27 patient interviews and 126 phone interviews per month were performed. Improvements to the instruments used for patient agenda management were made, positively impacting compliance (+13%) with waiting time criteria.
Conclusions
CNSs were successfully introduced into all identified disease pathways and played an active role within the MDTs. Although there are data in literature indicating optimal CNS staffing for specific cancers, there are no previous Italian experiences that can be used for comparative purposes. We need to better clarify how disease characteristics and the number of new patients influence CNS staffing in our specific organizational care context, which obviously differs from that of other countries. Measuring CNS activities and outcomes would also help to optimize CNS core activities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Istituto Scientifico Romagnolo per lo Studio e per la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract